Faes Farma, S.a. · BME:FAE
Faes Farma — Q1 2024 Earnings Presentation
18 slides from Faes Farma's earnings presentation, April 2024
Slide 1: Business update Q1 2024
Business update Q1 2024 April 2024
Slide 2: Index
Index 1// 2// 3// Overview Business Results Q1 2024 update Q1 and Outlook 2024
Slide 3: Overview Q1 2024
Overview Q1 2024 oF FAES FARMA
Slide 4: Highlights
Overview Q1 2024 Highlights BUSINESS Positive start of 2024, with revenue growth driven mainly by pharma's strong performance in Spain and PERFORMANCE international markets. FINANCIAL Double-digit profit growth contributing to an increase in cash generation now that the final phases of the POSITION
Slide 5: Key figures
Overview Q1 2024 Key figures Total 139,4 M€ EBITDA* 41 M€ Income +7% +10% Income 58,3 M€ EBIT** 35,9 M€ top 3 +10% +5% molecules Total international 80,4 M€ Net profit 30,4 M€ +6% +10% income *Operating profit before depreciation and amortization ** Operating profit 5
Slide 6: Business update Q1 2024
2// Business update Q1 2024 6
Slide 7: Solid growth across the entire pharma portfolio
Business update Q1 2024 Solid growth across the entire pharma portfolio Total income by portfolio line Animal Pharma top 3 nutrition and M€ Q1 2024 Q1 2023 % molecules health Pharma 126,5 116,4 9% 42% 9% Pharma top 3 molecules 58,3 55,5 5% Rest of Pharma 68,2 61,0 12% Animal Nutrition and Health 12,
Slide 8: Evolution top 3 molecules
Business update Q1 2024 Evolution top 3 molecules Growth in all business areas driven by both new ophthalmic and orodispersible presentations, BILASTINE 38,9 M€ as well as, the international performance of the original tablet formats. +5% 15,2 M€ Growth led by the LATAM subsidiaries where sales doub
Slide 9: Growth driven by Pharma areas, with particularly strong performance in Spain
Business update Q1 2024 Growth driven by Pharma areas, with particularly strong performance in Spain Total income by business areas Q1 2024 Q1 2023 % M€ Animal nutrition and health Pharma Pharma 126,5 116,4 9% 9% Spain Pharma Spain 47,4 41,6 14% 34% Pharma International (without licences) 44,0 40,2
Slide 10: Pharma Spain. Strong start of the year in all sales channels
Business update Q1 2024 Pharma Spain. Strong start of the year in all sales channels INCOME SPAIN PHARMA Highlights Q1 2024 M€ Q1 2024 Q1 2023 %var PRESCRIPTION Spain Pharma 47,4 41,6 14% Good performance in the first quarter. Bilastine offsets price reductions with new ophthalmic and orodispersible
Slide 11: Pharma International (without licenses). Good performance especially in the new MEA project
Business update Q1 2024 Pharma International (without licenses). Good performance especially in the new MEA project INCOME INTERNATIONAL (without licenses) M€ Q1 2024 Q1 2023 %var Highlights Q1 2024 International (withour licenses) 44,0 40,2 9% Subsidiaries LATAM 20,5 20,0 2% Central American Caribb
Slide 12: Licenses. Moderate growth in line with expectations
Business update Q1 2024 Licenses. Moderate growth in line with expectations Highlights Q1 2024 INCOME LICENSES LICENSES BILASTINE Bilastine licensing performance remains positive, despite Q1 2024 Q1 2023 %var the maturity of the product, underpinned by: M€ • Strong sell out in core markets at the st
Slide 13: Animal nutrition and health. We continue to face challenges in the sector
Business update Q1 2024 Animal nutrition and health. We continue to face challenges in the sector INCOME FARM FAES Highlights Q1 2024 M€ Q1 2024 Q1 2023 %var Animal nutrition and health 12,9 13,6 -5% • Sales continue to be hampered by the lack of piglets due to emerging diseases, a situation that we
Slide 14: Results and Outlook
= “URE RR au” 377 Results and Outlook ms NRE Ae vc an
Slide 15: Double-digit profit growth
Results and Outlook Q1 2024 Double-digit profit growth Thousand € Q1 2024 Q1 2023 %change Ordinary income (sales) 131.133 118.450 10,7% Highlights Q1 2024 Other operating income 7.892 11.612 -32,0% work carried out by the company for its assets 406 0 - Tota Income 139.431 130.062 7,2% Cost of sales
Slide 16: 2024 Outlook
2024 Outlook In 2024, even with some major challenges on the horizon, we will continue to grow especially driven by our international business expansion Guidance 2024 Impacts + 2024 Impacts - 2024 Other issues with an impact on the P&L • Double-digit growth in • Increase in personnel 2024 LATAM & ME
Slide 17: Faes Farma - Caring for tomorrow, today
aF FAES FARMA Caring for tomorrow, today
Slide 18: Disclaimer
DISCLAIMER This presentation has been prepared and published by Faes Farma Group and is presented for informational purposes only. This presentation is not a brochure, nor is it an offer or recommendation to make an investment. This presentation does not imply any subscription commitment, nor an off